Pfizer Corporation

Raqualia Pharma Inc.

Katsuhiro Shinjyo

Seiji Nukui

Yoshiyuki Okumura

Kazunari Nakao

Akiyoshi Kawai

Tomoki Kato

Kana Taniguchi

Yoshinobu Hashizume

Miyako Matsumizu

Naomi Ueno

Yoriko Miyake

Naomi Uneo

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y, Y, Yand Yare independently selected from N, CH, etc.; Ris H, Calkyl, etc.; Qis a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is Calkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; Ris H, Calkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, Calkyl, etc.; m is 0, 1 or 2; Rand Rare independently selected from H and Calkyl ; Ris H, Calkyl, etc.; Qis a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamadin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y, Y, Yand Yare independently selected from N, CH, etc.; Ris H, Calkyl, etc.; Qis a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5&#x2013;6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is Calkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; Ris H, Calkyl, etc.; Z is a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, Calkyl, etc.; m is 0, 1 or 2; Rand Rare independently selected from H and Calkyl; Ris H, Calkyl, etc.; Qis a 5&#x2013;12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

Growing community of inventors

Aichi-ken, Japan

Katsuhiro Shinjyo